CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ: CERS) announced today that Hemakim, Cerus’
distributor for Turkey, has signed an agreement with the Florence
Nightingale Hospital, a leading medical center in Turkey, to supply the
INTERCEPT Blood System for platelets and plasma.
“With the adoption of the INTERCEPT Blood System, we know we are doing
everything in our power to provide patients with safe and effective
blood products, consistent with our mission to use innovative products
to continuously improve patient care,” said Dr. Hulya Bilgen, associate
professor and director of the Florence Nightingale Transfusion Center.
“We strive to provide our patients and their families with the best the
world can offer, with service from a qualified and experienced clinical
staff.”
“We are extremely proud that the INTERCEPT system meets Florence
Nightingale Hospital’s demanding standards for healthcare technologies,
and we share the Hospital’s passion for patient safety,” said Caspar
Hogeboom, president of Cerus Europe. “Including Turkey, customers in 18
countries have chosen the INTERCEPT Blood System to protect patients
from transfusion-transmitted diseases.”
The Florence Nightingale Hospital Group, based in Istanbul, Turkey,
offers patient-centered and specialized healthcare by integrating
education, research and technology with clinical care. The group was
founded in 1989, under the body of Turkish Cardiology Foundation, as the
first cardiovascular disease hospital in the region. Today, with four
general hospitals, a medical center, a teaching hospital, a clinical
research center and a Hi-Tech hospital, the Florence Nightingale
Hospital Group is one of the largest and most reputed hospitals in
Europe and the Middle East.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused on
commercializing the INTERCEPT Blood System to enhance blood safety. The
INTERCEPT system is designed to reduce the risk of
transfusion-transmitted diseases by inactivating a broad range of
pathogens such as viruses, bacteria and parasites that may be present in
donated blood. The nucleic acid targeting mechanism of action enables
INTERCEPT treatment to inactivate established transfusion threats, such
as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed
to inactivate emerging pathogens such as influenza, malaria and dengue.
Cerus currently markets and sells the INTERCEPT Blood System for both
platelets and plasma in Europe, the Commonwealth of Independent States,
the Middle East and selected countries in other regions around the
world. The INTERCEPT red blood cell system is in clinical development.
See http://www.cerus.com
for more information.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
Source: Cerus Corporation